13,196 views
http://www.medicinaeinformazione.com/ Ovarian cancer, among the various gynecological tumors, is certainly the most difficult to detect because there is no test capable of leading to an early diagnosis, because the symptoms are common to other benign pathologies and therefore are often underestimated and consequently a diagnosis is often made when the tumor is in an advanced stage. However, today with cutting-edge surgery and increasingly targeted therapies it is possible to manage it over time. We talk about all this with Professor Nicoletta Colombo, Director of the Division of Medical Oncological Gynecology of the IEO, European Institute of Oncology in Milan who talks to us about the role of genetic tests on the mutation of the BRCA1 and BRCA2 genes not only in determining a family risk factor (as recently discussed in the case of the actress Angelina Jolie) but also in the development of targeted therapies that can stop the angiogenesis of the tumor, the creation of neovessels that vascularize the tumor and carries the risk of spreading the disease. The Professor talks to us about the importance of not underestimating symptoms that continue over time even if they are unfortunately symptoms often similar to those of the most common gynecological disorders, the importance of a correct diagnosis with instrumental tests and blood markers (Ca125) of surgery performed correctly in reference centers and above all of targeted therapies that today combine well-established chemotherapies with new biological drugs that allow the control of the disease over time especially if discovered in a non-advanced phase. Professor Colombo then addresses the delicate issue of young women who want to get pregnant after the disease and explains how it is possible today and finally talks to us about replacement therapies in menopause, for which women they are recommended and what risks they may entail.